FDA Promotes Personalized Medicine - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

FDA Promotes Personalized Medicine



FDA is undertaking a spectrum of initiatives to encourage the development of drugs and medical products linked to patient subtypes. At a briefing to unveil a new report on these activities, commissioner Margaret Hamburg discussed how a deeper understanding of the underlying mechanisms of disease has made it possible for FDA to approve new cancer drugs for patients with specifically characterized tumors, as well as a new treatment for cystic fibrosis effective in patients with a specific gene mutation. Agency researchers are developing methods for refining dosing regimens by examining genetic factors that may affect how much of a drug enters the blood stream. Richard Pazdur, director of FDA’s Center for Drug Evaluation and Research’s Office of Oncology & Hematology products, predicted that smaller clinical trials for targeted cancer treatments will be possible by using platforms for universal testing of known biomarkers. “Paving the Way for Personalized Medicine” is available at www.fda.gov.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
26%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
10%
All of the above.
43%
No government involvement in patient treatment or drug development.
10%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?

Click here